{"classes":[{"categories":[{"measurements":[{"comment":"No events occurred, intervals are incalculable","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"Will be estimated by the number of patients who achieve a VGPR, complete response (CR), or stringent complete response (sCR) at any time divided by the total number of evaluable patients. Exact binomial 95% confidence intervals for the true success rate will be calculated.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive ixazomib citrate PO on days 1, 8, 15, 29, 36, 43, 57, 64, and 71 and pembrolizumab IV over 30 minutes on days 1, 22, 43, 64. Patients also receive dexamethasone PO on days 1, 8, 15, 29, 36, 43, 57, 64, and 71. Cycles with dexamethasone repeat every 84 days for up to 1 year and cycles with ixazomib citrate and pembrolizumab repeat every 84 days for up to 2 years in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Ixazomib Citrate, Pembrolizumab, and Dexamethasone)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 9 months","title":">= Very Good Partial Response (VGPR) Response Percentage With Pembrolizumab Added to Ixazomib Citrate and Dexamethasone","type":"SECONDARY","unitOfMeasure":"percentage of responders"}